John Houston has been named president and CEO of Arvinas. He will also join the board of directors of the New Haven, CT, drug developer. Houston initially joined Arvinas in January as president of research and development and chief scientific officer. Before Arvinas, Houston spent 18 years in various roles at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]). Arvinas is developing a new class of drugs that use the body’s protein disposal system to potentially treat cancer and other diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
